Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRK1A, 1B, 2-4) and cdc2-like kinases (CLK1-4) belong to the CMGC group of serine/threonine kinases. These protein kinases are involved in multiple cellular functions, including intracellular signaling, mRNA splicing, chromatin transcription, DNA damage repair, cell survival, cell cycle control, differentiation, homocysteine/methionine/folate regulation, body temperature regulation, endocytosis, neuronal development, synaptic plasticity, etc. Abnormal expression and/or activity of some of these kinases, DYRK1A in particular, is seen in many human nervous system diseases, such as cognitive deficits associated with Down syndrome, Alzheimer’s disease and related diseases, tauopathies, dementia, Pick’s disease, Parkinson’s disease and other neurodegenerative diseases, Phelan-McDermid syndrome, autism, and CDKL5 deficiency disorder. DYRKs and CLKs are also involved in diabetes, abnormal folate/methionine metabolism, osteoarthritis, several solid cancers (glioblastoma, breast, and pancreatic cancers) and leukemias (acute lymphoblastic leukemia, acute megakaryoblastic leukemia), viral infections (influenza, HIV-1, HCMV, HCV, CMV, HPV), as well as infections caused by unicellular parasites (Leishmania, Trypanosoma, Plasmodium). This variety of pathological implications calls for (1) a better understanding of the regulations and substrates of DYRKs and CLKs and (2) the development of potent and selective inhibitors of these kinases and their evaluation as therapeutic drugs. This article briefly reviews the current knowledge about DYRK/CLK kinases and their implications in human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The BioPlex network: a systematic exploration of the human interactome
Huttlin, E. L., Ting, L., Bruckner, R. J., Gebreab, F., Gygi, M. P., Szpyt, J., Tam, S., Zarraga, G., Colby, G., Baltier, K., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.043 · Cited by 1,425 · cited 1×
“Other large-scale interactome studies provide information on proteins binding to DYRKs and CLKs [76,77].”
BackgroundThe specificities of protein kinase inhibitors: an update
BAIN, J., McLAUCHLAN, H., ELLIOTT, M., & COHEN, P. (2003) · Biochemical Journal · doi:10.1042/bj20021535 · Cited by 1,369 · cited 1×
“A few representative pharmacological inhibitors: AnnH75 [51], EGCG [255], EHT-1610 [55], Harmine [256], INDY [44], Leucettine L41 [43,257], Lorecivivint [258,259], GNF4877 [170,179], MU1210 [68], and TCMDC-135051 [251,252].”
A Human Interactome in Three Quantitative Dimensions Organized by Stoichiometries and Abundances
Hein, M. Y., Hubner, N. C., Poser, I., Cox, J., Nagaraj, N., Toyoda, Y., Gak, I. A., Weisswange, I., Mansfeld, J., Buchholz, F., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.053 · Cited by 1,270
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457
Kimura, R., Kamino, K., Yamamoto, M., Nuripa, A., Kida, T., Kazui, H., Hashimoto, R., Tanaka, T., Kudo, T., Yamagata, H., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl437 · Cited by 281
Duchon, A., & Herault, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00104 · Cited by 181
Wang, P., Karakose, E., Liu, H., Swartz, E., Ackeifi, C., Zlatanic, V., Wilson, J., González, B. J., Bender, A., Takane, K. K., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.005 · Cited by 162
CLK2 inhibition ameliorates autistic features associated with SHANK3 deficiency
Bidinosti, M., Botta, P., Krüttner, S., Proenca, C. C., Stoehr, N., Bernhard, M., Fruh, I., Mueller, M., Bonenfant, D., Voshol, H., et al. (2016) · Science · doi:10.1126/science.aad5487 · Cited by 151 · cited 4×
“CLK2 Autism Phelan-McDermid syndrome (PMDS) [239] [65]”
InfluentialJi, J., Lee, H., Argiropoulos, B., Dorrani, N., Mann, J., Martinez-Agosto, J. A., Gomez-Ospina, N., Gallant, N., Bernstein, J. A., Hudgins, L., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.71 · Cited by 145
García-Cerro, S., Martínez, P., Vidal, V., Corrales, A., Flórez, J., Vidal, R., Rueda, N., Arbonés, M. L., & Martínez-Cué, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106572 · Cited by 104
DYRK1A: a potential drug target for multiple down syndrome neuropathologies
Becker, W., Soppa, U., & Tejedor, F. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660186 · Cited by 103
Yin, X., Jin, N., Shi, J., Zhang, Y., Wu, Y., Gong, C.-X., Iqbal, K., & Liu, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-00682-y · Cited by 93
Altafaj, X., Martín, E. D., Ortiz-Abalia, J., Valderrama, A., Lao-Peregrín, C., Dierssen, M., & Fillat, C. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.11.017 · Cited by 75
Neumann, F., Gourdain, S., Albac, C., Dekker, A. D., Bui, L. C., Dairou, J., Schmitz-Afonso, I., Hue, N., Rodrigues-Lima, F., Delabar, J. M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20984-z · Cited by 71
Altered Hippocampal-Prefrontal Neural Dynamics in Mouse Models of Down Syndrome
Chang, P., Bush, D., Schorge, S., Good, M., Canonica, T., Shing, N., Noy, S., Wiseman, F. K., Burgess, N., Tybulewicz, V. L. J., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.065 · Cited by 47
Disease Association and Druggability of WD40 Repeat Proteins
Song, R., Wang, Z.-D., & Schapira, M. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00451 · Cited by 45 · cited 1×
“However, we would like to mention WDR68, also known as DCAF7 (DDB1-associated and CUL4-associated factor 7) or HAN11 (Human homolog of the Petunia hybrida an11 gene), a scaffolding protein of the WD40-repeat protein family [78] that binds class 1 DYRKs and HIPK2 (Homeodomain-interacting protein kinase 2).”
Background
Cited by
The Omnipresence of DYRK1A in Human Diseases
Deboever, E., Fistrovich, A., Hulme, C., & Dunckley, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169355 · Cited by 77
State-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
On the possibility of yet a third kinetochore system in the protist phylum Euglenozoa
Benz, C., Raas, M. W. D., Tripathi, P., Faktorová, D., Tromer, E. C., Akiyoshi, B., & Lukeš, J. (2024) · mBio · doi:10.1128/mbio.02936-24 · Cited by 18
Metadata
- Authors
- Lindberg, M. F., & Meijer, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-06-03
- Volume
- 22
- Issue
- 11
- Pages
- 6047
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3166351730
- Cited by
- 112
- References
- 18
- FWCI
- 5.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.